HC Wainwright Brokers Decrease Earnings Estimates for SNDX

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) – Analysts at HC Wainwright dropped their Q3 2026 earnings per share (EPS) estimates for Syndax Pharmaceuticals in a research note issued to investors on Wednesday, August 5th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($0.48) per share for the quarter, down from their previous forecast of ($0.21). HC Wainwright currently has a “Buy” rating and a $38.00 target price on the stock. The consensus estimate for Syndax Pharmaceuticals’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Syndax Pharmaceuticals’ Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.92) EPS, FY2027 earnings at ($0.41) EPS and FY2028 earnings at $0.84 EPS.

A number of other research analysts have also weighed in on the stock. UBS Group reaffirmed a “buy” rating on shares of Syndax Pharmaceuticals in a research note on Friday, June 12th. Weiss Ratings lowered shares of Syndax Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. Bank of America reaffirmed a “buy” rating on shares of Syndax Pharmaceuticals in a research report on Wednesday. Finally, Barclays raised their price target on shares of Syndax Pharmaceuticals from $35.00 to $37.00 and gave the company an “overweight” rating in a research report on Friday, May 1st. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $42.36.

Syndax Pharmaceuticals Stock Performance

Shares of SNDX stock opened at $19.76 on Friday. The company has a current ratio of 6.77, a quick ratio of 5.06 and a debt-to-equity ratio of 38.95. The firm has a fifty day simple moving average of $20.41 and a two-hundred day simple moving average of $21.37. Syndax Pharmaceuticals has a 12 month low of $12.10 and a 12 month high of $25.59. The firm has a market capitalization of $1.75 billion, a PE ratio of -7.87 and a beta of 0.40.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Tuesday, August 4th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.10). Syndax Pharmaceuticals had a negative return on equity of 372.94% and a negative net margin of 87.52%.The firm had revenue of $72.79 million during the quarter, compared to the consensus estimate of $79.36 million. During the same quarter in the prior year, the business earned ($0.83) earnings per share. Syndax Pharmaceuticals’s revenue for the quarter was up 91.8% on a year-over-year basis.

Insider Buying and Selling at Syndax Pharmaceuticals

In other news, CMO Nicholas A.J. Botwood sold 34,280 shares of the stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $18.00, for a total value of $617,040.00. Following the completion of the sale, the chief marketing officer owned 60,885 shares in the company, valued at $1,095,930. This represents a 36.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Michael A. Metzger sold 32,375 shares of the firm’s stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $24.24, for a total transaction of $784,770.00. Following the transaction, the chief executive officer directly owned 484,843 shares in the company, valued at $11,752,594.32. The trade was a 6.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 105,914 shares of company stock worth $2,120,789. Company insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Torray Investment Partners LLC purchased a new stake in shares of Syndax Pharmaceuticals during the 4th quarter worth approximately $2,055,000. Eventide Asset Management LLC lifted its stake in Syndax Pharmaceuticals by 25.3% in the fourth quarter. Eventide Asset Management LLC now owns 1,238,196 shares of the company’s stock valued at $26,014,000 after purchasing an additional 249,710 shares during the last quarter. Orbimed Advisors LLC bought a new position in Syndax Pharmaceuticals during the first quarter valued at $22,479,000. Voss Capital LP bought a new position in Syndax Pharmaceuticals during the fourth quarter valued at $2,626,000. Finally, Apis Capital Advisors LLC increased its position in Syndax Pharmaceuticals by 13.5% in the fourth quarter. Apis Capital Advisors LLC now owns 724,000 shares of the company’s stock worth $15,211,000 after buying an additional 86,000 shares during the last quarter.

Syndax Pharmaceuticals News Summary

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Syndax and set a $38 price target, despite lowering its target from $40. The revised target still implies significant upside from recent trading levels. Benzinga analyst price target report
• Neutral Sentiment: Syndax granted inducement stock options covering up to 59,250 shares to five new employees. The awards support hiring and retention, but could modestly dilute existing shareholders as the options vest over four years. Syndax inducement grants announcement
• Negative Sentiment: HC Wainwright reduced its long-term EPS forecasts, cutting its FY2029 estimate to $2.28 from $2.59 and its FY2030 estimate to $3.16 from $3.52. Although the firm remains bullish, the revisions and lower price target suggest more cautious expectations for future profitability.
• Negative Sentiment: Syndax’s second-quarter performance added pressure: the company reported a loss of $0.55 per share versus the expected $0.45 loss, while revenue of $72.79 million came in below the $79.36 million consensus. Revenue nonetheless increased 91.8% year over year, indicating strong commercial growth despite the earnings miss. Syndax Q2 2026 earnings call transcript

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.